[go: up one dir, main page]

EE200200349A - Antiprogestiinsete omadustega ravimite manustamise vahendid - Google Patents

Antiprogestiinsete omadustega ravimite manustamise vahendid

Info

Publication number
EE200200349A
EE200200349A EEP200200349A EEP200200349A EE200200349A EE 200200349 A EE200200349 A EE 200200349A EE P200200349 A EEP200200349 A EE P200200349A EE P200200349 A EEP200200349 A EE P200200349A EE 200200349 A EE200200349 A EE 200200349A
Authority
EE
Estonia
Prior art keywords
drugs
administration
antiprogestin
properties
antiprogestin properties
Prior art date
Application number
EEP200200349A
Other languages
English (en)
Inventor
Jukarainen Harri
Markkula Tommi
Ala-Sorvari Juha
Lehtinen Matti (Surnud)
Ruohonen Jarkko
Haapakumpu Timo
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of EE200200349A publication Critical patent/EE200200349A/et
Publication of EE05123B1 publication Critical patent/EE05123B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
    • C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C08G77/18—Polysiloxanes containing silicon bound to oxygen-containing groups to alkoxy or aryloxy groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/44—Block-or graft-polymers containing polysiloxane sequences containing only polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/48—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
    • C08G77/50—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EEP200200349A 1999-12-23 2000-11-21 Antiprogestiinsete omadustega ravimite manustamise vahendid EE05123B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/472,126 US6476079B1 (en) 1999-12-23 1999-12-23 Devices for the delivery of drugs having antiprogestinic properties
PCT/FI2000/001013 WO2001047490A1 (en) 1999-12-23 2000-11-21 Devices for the delivery of drugs having antiprogestinic properties

Publications (2)

Publication Number Publication Date
EE200200349A true EE200200349A (et) 2003-08-15
EE05123B1 EE05123B1 (et) 2009-02-16

Family

ID=23874296

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200349A EE05123B1 (et) 1999-12-23 2000-11-21 Antiprogestiinsete omadustega ravimite manustamise vahendid

Country Status (31)

Country Link
US (1) US6476079B1 (et)
EP (1) EP1239829B1 (et)
JP (1) JP4895150B2 (et)
KR (1) KR100850548B1 (et)
CN (1) CN100346772C (et)
AR (1) AR026647A1 (et)
AT (1) ATE401859T1 (et)
AU (1) AU781555B2 (et)
BR (1) BR0016697A (et)
CA (1) CA2395226C (et)
CO (1) CO5261571A1 (et)
CZ (1) CZ301865B6 (et)
DE (2) DE1239829T1 (et)
DK (1) DK1239829T3 (et)
EE (1) EE05123B1 (et)
ES (1) ES2310526T3 (et)
HK (1) HK1047235B (et)
HU (1) HU229438B1 (et)
IL (2) IL149663A0 (et)
MX (1) MXPA02006174A (et)
NO (1) NO332261B1 (et)
NZ (1) NZ519876A (et)
PE (1) PE20010801A1 (et)
PL (1) PL201216B1 (et)
PT (1) PT1239829E (et)
RU (1) RU2228170C2 (et)
SK (1) SK287229B6 (et)
TW (1) TWI248367B (et)
UA (1) UA70401C2 (et)
WO (1) WO2001047490A1 (et)
ZA (1) ZA200203620B (et)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887948B2 (en) * 1998-06-30 2005-05-03 Schering Oy Method for preparing a siloxane-based elastomer composition
US6794464B2 (en) 1998-06-30 2004-09-21 Schering Oy Membrane or matrix for controlling the permeation rate of drugs
AU2002210580A1 (en) * 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
JP2005503389A (ja) * 2001-08-31 2005-02-03 シエーリング オサケユイチア 薬物送達システム
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
DK1696822T3 (da) * 2003-11-13 2010-05-17 Psivida Inc Injicerbart vedvarende frigørelsesimplantat, som har en bioeroderbar matrixkerne og en bioeroderbar hus
RU2283637C1 (ru) * 2005-03-22 2006-09-20 Общество с ограниченной ответственностью "Производственно-коммерческая фирма "Две линии" Пластырь
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
EP1933936B1 (en) 2005-10-13 2019-03-20 Synthes GmbH Drug-impregnated encasement
US20070149916A1 (en) * 2005-12-22 2007-06-28 Alza Corporation Dry matrices as drug reservoirs in electrotransport applications
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
EP2057972A1 (en) * 2007-11-07 2009-05-13 N.V. Organon Intrauterine deposit
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US11992431B2 (en) 2008-09-17 2024-05-28 Bayer Oy Inserter
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
PT2349143E (pt) 2008-09-17 2013-07-08 Bayer Oy Um dispositivo de inserção
ES2673294T3 (es) * 2008-11-06 2018-06-21 Novo Nordisk A/S Dispositivo de administración de fármacos asistido electrónicamente
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US8568374B2 (en) * 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
SG10201504913UA (en) * 2010-03-22 2015-07-30 Repros Therapeutics Inc Compositions and methods for non-toxic delivery of antiprogestins
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
RU2607179C2 (ru) * 2011-07-20 2017-01-10 Патрик Ф. КАЙЗЕР Интравагинальные устройства для доставки лекарственных средсв
TWI590843B (zh) 2011-12-28 2017-07-11 信迪思有限公司 膜及其製造方法
EP2890760A4 (en) 2012-08-30 2016-10-12 Atrp Solutions Inc DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
CN105263978B (zh) 2013-02-04 2018-04-17 Atrp解决方案公司 耐盐星形大分子
EP2953678B1 (en) 2013-02-06 2020-03-25 Sillender, Mark Therapeutic substance transfer catheter
WO2014121333A1 (en) 2013-02-06 2014-08-14 Sillender Mark Embryo transfer catheter and method
WO2014160305A1 (en) * 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
CA2909121C (en) 2013-04-11 2021-02-09 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US20160144067A1 (en) 2013-06-21 2016-05-26 DePuy Synthes Products, Inc. Films and methods of manufacture
WO2015023811A2 (en) 2013-08-16 2015-02-19 The J. David Gladstone Institutes Compositions and methods for identifying latently infected cells
ES2699003T3 (es) * 2014-06-28 2019-02-06 Laboratorios Andromaco S A Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, usado para la prevención de partos prematuros
EP3164429A4 (en) 2014-07-03 2017-12-20 ATRP Solutions, Inc. Surfactant-compatible star macromolecules
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
KR102314914B1 (ko) * 2015-03-05 2021-10-21 듀폰 도레이 스페셜티 머티리얼즈 가부시키가이샤 경화성 유기폴리실록산 조성물, 그의 용도, 및 그 조성물로부터 제조된 라미네이트
CA2985717A1 (en) * 2015-05-13 2016-11-17 Bayer Oy A long acting drug delivery device and its use in contraception
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
JP7058610B2 (ja) 2016-06-07 2022-04-22 ザ・ジェイ・デイヴィッド・グラッドストーン・インスティトゥーツ ベータ－ヒドロキシブチレート及びブタンジオールの中鎖脂肪酸エステル並びに組成物、並びにそれを使用するための方法
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
JP7476198B2 (ja) 2018-08-22 2024-04-30 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン 心臓弁疾患を治療するための医薬組成物
JP7495435B2 (ja) 2019-06-14 2024-06-04 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン 治療用干渉粒子による免疫不全ウイルス感染を処置するための組成物及び方法
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
TWI803052B (zh) * 2021-11-12 2023-05-21 佛教慈濟醫療財團法人 經皮遞送裝置及其使用及製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
JPS519003B1 (et) * 1970-11-07 1976-03-23
US3836560A (en) 1971-03-08 1974-09-17 Union Carbide Corp Organosilicone polymers
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4323488A (en) * 1979-03-26 1982-04-06 Shin-Etsu Chemical Company Limited Method for the preparation of silicone-modified polyoxyalkylene polyethers and room temperature-curable compositions therewith
JPS60148560A (ja) * 1984-01-17 1985-08-05 富士システムズ株式会社 皮膚用封止材
CA1257727A (en) * 1984-12-18 1989-07-18 Chi-Long Lee Hydrophilic silicone-organic copolymer elastomers
US4600751A (en) * 1984-12-18 1986-07-15 Dow Corning Corporation Hydrophilic silicone-organic copolymer elastomers
GB8704755D0 (en) * 1987-02-28 1987-04-01 Dow Corning Ltd Pharmaceutical delivery device
US4951657A (en) * 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
EP0545002A1 (en) 1991-11-21 1993-06-09 Kose Corporation Silicone polymer, paste-like composition and water-in-oil type cosmetic composition comprising the same
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
JP3201940B2 (ja) * 1995-09-12 2001-08-27 信越化学工業株式会社 硬化性シリコーンエラストマー組成物及びその製造方法
US5811487A (en) * 1996-12-16 1998-09-22 Dow Corning Corporation Thickening silicones with elastomeric silicone polyethers
US5889108A (en) 1997-06-02 1999-03-30 Dow Corning Corporation Thickening solvents with elastomeric silicone polyethers
US6013711A (en) 1997-06-18 2000-01-11 Ck Witco Corporation Hydrophilic polysiloxane compositions
FI103051B1 (fi) 1997-08-22 1999-04-15 Leiras Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens

Also Published As

Publication number Publication date
HUP0204015A3 (en) 2004-06-28
HK1047235B (en) 2009-04-24
HK1047235A1 (en) 2003-02-14
SK287229B6 (sk) 2010-03-08
CN100346772C (zh) 2007-11-07
DE60039626D1 (de) 2008-09-04
US6476079B1 (en) 2002-11-05
EE05123B1 (et) 2009-02-16
PE20010801A1 (es) 2001-08-09
AR026647A1 (es) 2003-02-19
MXPA02006174A (es) 2002-12-05
CZ301865B6 (cs) 2010-07-14
IL149663A (en) 2007-02-11
CA2395226C (en) 2009-01-27
NZ519876A (en) 2004-02-27
ATE401859T1 (de) 2008-08-15
JP4895150B2 (ja) 2012-03-14
CN1420762A (zh) 2003-05-28
NO332261B1 (no) 2012-08-13
WO2001047490A1 (en) 2001-07-05
PT1239829E (pt) 2008-10-09
HU229438B1 (hu) 2013-12-30
NO20023012L (no) 2002-08-09
TWI248367B (en) 2006-02-01
PL201216B1 (pl) 2009-03-31
ES2310526T3 (es) 2009-01-16
UA70401C2 (uk) 2004-10-15
SK7012002A3 (en) 2003-01-09
NO20023012D0 (no) 2002-06-21
JP2003518482A (ja) 2003-06-10
KR20020067573A (ko) 2002-08-22
DE1239829T1 (de) 2003-02-06
AU781555B2 (en) 2005-06-02
EP1239829B1 (en) 2008-07-23
CZ20022106A3 (cs) 2002-11-13
AU1710201A (en) 2001-07-09
PL355994A1 (en) 2004-05-31
CO5261571A1 (es) 2003-03-31
IL149663A0 (en) 2002-11-10
EP1239829A1 (en) 2002-09-18
CA2395226A1 (en) 2001-07-05
BR0016697A (pt) 2002-09-03
HUP0204015A2 (en) 2003-05-28
KR100850548B1 (ko) 2008-08-06
DK1239829T3 (da) 2008-11-24
RU2228170C2 (ru) 2004-05-10
RU2002119587A (ru) 2004-02-27
ZA200203620B (en) 2003-07-30

Similar Documents

Publication Publication Date Title
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
PT1221918E (pt) Administracao de drogas sub-tenon
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
DE60016271D1 (de) Medikamentenzuführvorrichtung
ATE289500T1 (de) Ophtalmologische medikamentenzuführvorrichtung
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
IS6310A (is) Kínasólínafleiður til lækninga
DE60037203D1 (de) Medikamentenspender
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
NO20015175L (no) Farmasöytisk sammensetning
DE69935681D1 (de) Vorrichtungen zur Medikamentverabreichung
DE60019312D1 (de) Medizinische laserfeste fassvorrichtung
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20014035D0 (no) System for oral administrasjon av medikament
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
PT1200092E (pt) Farmacos de beta-carbolina
NO20015670L (no) Forbedrede farmasöytiske formuleringer
PT1239832E (pt) Composicoes farmaceuticas
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
IS6163A (is) Lyfjakomplex
DE69934902D1 (de) Medikament gegen drogenabhängigkeit
ATE362915T1 (de) Heterocyclische derivate und arzneistoffe
NO20004816D0 (no) Ny farmasøytisk formulering
IT1316440B1 (it) Cannula erogatrice di unguenti medicinali.

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20151121